Roselena Silvestri Schuh
Universidade Federal do Rio Grande do Sul
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Roselena Silvestri Schuh.
Química Nova | 2014
Roselena Silvestri Schuh; Fernanda Bruxel; Helder Ferreira Teixeira
Nanoemulsions composed of a medium-chain triglyceride oil core stabilized by rapeseed or sunflower lecithins were prepared by spontaneous emulsification and high-pressure homogenization. These nanoemulsions are compared with formulations stabilized by egg lecithin. Nanoemulsions obtained by high-pressure homogenization display larger droplet size (230 to 440 nm) compared with those obtained by spontaneous emulsification (190 to 310 nm). The zeta potentials of the emulsions were negative and below -25 mV. Zeta potential inversion occurred between pH 3.0 and 4.0. The results demonstrate the feasibility of preparing lipid emulsions comprising rapeseed or sunflower lecithins by spontaneous emulsification and high-pressure homogenization.
Expert Opinion on Drug Delivery | 2016
Roselena Silvestri Schuh; Guilherme Baldo; Helder Ferreira Teixeira
ABSTRACT Introduction: Mucopolysaccharidoses (MPS) are genetic disorders caused by the accumulation of glycosaminoglycans due to deficiencies in the lysosomal enzymes responsible for their catabolism. Current treatments are not fully effective and are not available for all MPS types. Accordingly, researchers have tested novel therapies for MPS, including nanotechnology-based enzyme delivery systems and gene therapy. In this review, we aim to analyze some of the approaches involving nanotechnology as alternative treatments for MPS. Areas covered: We analyze nanotechnology-based systems, focusing on the biomaterials, such as polymers and lipids, that comprise these nanostructures, and we have highlighted studies that describe their use as enzyme and gene delivery systems for the treatment of MPS diseases. Expert opinion: Some protocols, such as the use of polymer-based systems or nanostructured carriers associated with enzymes and nanotechnology-based carriers for gene therapy, along with combined approaches, seem to be the future of MPS therapy.
International Journal of Nanomedicine | 2017
Michelle Fraga; Talita Giacomet de Carvalho; Juliana Bidone; Roselena Silvestri Schuh; Ursula da Silveira Matte; Helder Ferreira Teixeira
Mucopolysaccharidosis type I (MPS I) is an autosomal disease caused by alpha-l-iduronidase (IDUA) deficiency. This study used IDUA knockout mice as a model to evaluate whether parameters such as dose of plasmid and time of treatment could influence the transfection efficiency of complexes formed with PEGylated cationic nanoemulsions and plasmid (pIDUA), which contains the gene that encodes for IDUA. Formulations were composed of medium chain triglycerides, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(amino[polyethylene glycol]-2000), 1,2-dioleoyl-sn-glycero-3-trimethylammonium propane (DOTAP), glycerol, and water and were prepared by the adsorption or encapsulation of preformed pIDUA–DOTAP complexes by high-pressure homogenization. A progressive increase in IDUA expression was observed with an increase in the dose and time of transfection for mice treated with both complexes (adsorbed and encapsulated), especially in the liver. Regardless of the complex administered, a significant increase in IDUA activity was detected in lungs and liver compared with nontreated MPS I when a dose of 60 μg was administered and IDUA activity was measured 7 days postadministration. Tissue sections of major organs showed no presence of cell necrosis, inflammatory infiltrate, or an increase in apoptosis. Furthermore, immunohistochemistry for CD68 showed no difference in the number of macrophage cells in treated and nontreated animals, indicating the absence of inflammatory reaction caused by the treatment. The data set obtained in this study allowed establishing that factors such as dose and time can influence transfection efficiency in different degrees and that these complexes did not lead to any lethal effect in the MPS I murine model used.
Journal of Analytical Toxicology | 2014
Kristiane de Cássia Mariotti; Roselena Silvestri Schuh; Priscila Ferranti; Rafael S. Ortiz; Daniele Z. Souza; Flavio Pechansky; Pedro Eduardo Fröehlich; Renata Pereira Limberger
Brazil is considered one of the countries with the highest number of amphetamine-type stimulant (ATS) users worldwide, mainly diethylpropion (DIE) and fenproporex (FEN). The use of ATS is mostly linked to diverted prescription stimulants and this misuse is widely associated with (ab)use by drivers. A validated method was developed for the simultaneous analysis of amphetamine (AMP), DIE and FEN in plasma samples employing direct immersion-solid-phase microextraction, and gas chromatographic/mass spectrometric analysis. Trichloroacetic acid 10% was used for plasma deproteinization. In situ derivatization with propylchloroformate was employed. The linear range of the method covered from 5.0 to 100 ng/mL. The detection limits were 1.0 (AMP), 1.5 (DIE) and 2.0 ng/mL (FEN). The accuracy assessment of the control samples was within 85.58-108.33% of the target plasma concentrations. Recoveries ranged from 46.35 to 84.46% and precision was <15% of the value of relative standard deviation. This method is appropriate for screening and confirmation in plasma forensic toxicology analyses of these basic drugs.
European Journal of Pharmaceutics and Biopharmaceutics | 2018
Roselena Silvestri Schuh; Talita Giacomet de Carvalho; Roberto Giugliani; Ursula da Silveira Matte; Guilherme Baldo; Helder Ferreira Teixeira
Graphical abstract Figure. No Caption available. Abstract Mucopolysaccharidosis type I (MPS I) is an inherited disease caused by the deficiency of alpha‐L‐iduronidase (IDUA). This study shows the use of nanoemulsions co‐complexed with the plasmid of CRISPR/Cas9 system and a donor oligonucleotide aiming at MPS I gene editing in vitro. Nanoemulsions composed of MCT, DOPE, DOTAP, DSPE‐PEG, and water were prepared by high‐pressure homogenization. The DNA was complexed by adsorption (NA) or encapsulation (NE) of preformed DNA/DOTAP complexes with nanoemulsions at +4/−1 charge ratio. The incubation in pure DMEM or supplemented with serum showed that the complexation with DNA was stable after 1 h of incubation, but the complexes tended to release the adsorbed DNA after 24 h of incubation, while the encapsulated DNA remained complexed in the oil core of the nanoemulsions even 48 h after incubation with DMEM. The treatment of MPS I patient’s fibroblasts homozygous for the p.Trp402* mutation led to a significant increase in IDUA activity at 2, 15, and 30 days when compared to MPS I untreated fibroblasts. Flow cytometry and confocal microscopy demonstrated that there was a reduction in the area of lysosomes to values similar to normal, an indicator of correction of the cellular phenotype. These results show that the nanoemulsions co‐complexed with the CRISPR/Cas9 system and a donor oligonucleotide could effectively transfect MPS I p.Trp402* patient’s fibroblasts, as well as enable the production of IDUA, and represent a potential new treatment option for MPS I.
Química Nova | 2008
Regina Felisberto; Lucio Olimpio Vieira; Alessandra Couto; Roselena Silvestri Schuh; Caroline Thiessen Albino; Curso Técnico; Escola Técnica; Rua Ramiro Barcelos; Ana Cristina; Borba da Cunha
FROM RESIDUE TO INPUT: BUILDING A ROAD TO CLEAN CHEMISTRY THROUGH AN EDUCATIONAL PROJECT. The discussion among teachers, students, and technicians about the destination of residues from chemistry laboratories led to a research project whose results were incorporated into a course in its daily practices. The treatment of the residues from argentimetric practices allowed us to establish cognitive relations of technological basis and of those related to the rising of the level of awareness about environmental aspects and social responsibility of chemistry professionals. The techniques and the results, from the economic point of view, namely that of value aggregation (metallic silver) and the conversion of the residue into input (potassium chromate solution) are shown.
International Journal of Pharmaceutics | 2017
Helder Ferreira Teixeira; Fernanda Bruxel; Michelle Fraga; Roselena Silvestri Schuh; Giovanni K. Zorzi; Ursula da Silveira Matte; Elias Fattal
Since the first clinical studies, knowledge in the field of gene therapy has advanced significantly, and these advances led to the development and subsequent approval of the first gene medicines. Although viral vectors-based products offer efficient gene expression, problems related to their safety and immune response have limited their clinical use. Thus, design and optimization of nonviral vectors is presented as a promising strategy in this scenario. Nonviral systems are nanotechnology-based products composed of polymers or lipids, which are usually biodegradable and biocompatible. Cationic liposomes are the most studied nonviral carriers and knowledge about these systems has greatly evolved, especially in understanding the role of phospholipids and cationic lipids. However, the search for efficient delivery systems aiming at gene therapy remains a challenge. In this context, cationic nanoemulsions have proved to be an interesting approach, as their ability to protect and efficiently deliver nucleic acids for diverse therapeutic applications has been demonstrated. This review focused on cationic nanoemulsions designed for gene therapy, providing an overview on their composition, physicochemical properties, and their efficacy on biological response in vitro and in vivo.
Revista Brasileira De Farmacognosia-brazilian Journal of Pharmacognosy | 2013
Madson Ralide Fonseca Gomes; Roselena Silvestri Schuh; Ana Laura Bemvenuti Jacques; Gilcéia Guadagnin Dorneles; Jarbas Alves Montanha; Paulo Michel Roehe; Sergio Augusto de Loreto Bordignon; Eliane Dallegrave; Mirna Bainy Leal; Renata Pereira Limberger
The genus Drimys presents the widest geographical distribution of the Winteraceae family, which comprises seven genera and about 120 species. In Brazil, the genus is found from Bahia to Rio Grande do Sul and occur in two species, Drimys angustifolia Miers, and D. brasiliensis Miers, Winteraceae, popularly known as “cascade- anta”, characterized by the presence of fl avonoids and essential oils. It is used in folk medicine as an antiscorbutic, stimulant, antispasmodic, anti-diarrheal, antipyretic, antibacterial, and against asthma and bronchitis, besides having insecticidal properties. In addition to the known biological activities, it is very important to explore new applications in the treatment of physiological disorders or diseases caused by parasites. Based on this information, in this study we propose to evaluate volatile oils of the species D. brasiliensis and D. angustifolia, as an antioxidant, using the model of the DPPH radical as an antiviral against human herpes virus type 1 (HSV-1) and acute toxicity in vivo. The two species were not able to reduce the DPPH radical and showed interesting antiviral activity, signifi cantly reducing the virus titers in vitro assays. Regarding the in vivo toxicity in female Wistar rats, treatment with the two species showed interesting signs in animals such as salivation, ptosis, tremor, decreased motor activity. In addition the oils of D. brasiliensis to other signs, some animals showed increased urination and diarrhea.
Journal of Colloid and Interface Science | 2018
Roselena Silvestri Schuh; Édina Poletto; Flávia Nathiely Silveira Fachel; Ursula da Silveira Matte; Guilherme Baldo; Helder Ferreira Teixeira
In this study, we investigated the effects of the association of a single plasmid or its co-complexation along with an oligonucleotide on the physicochemical properties of cationic nanoemulsions and liposomes intended for gene editing. Formulations composed of DOPE, DOTAP, DSPE-PEG (liposomes), MCT (nanoemulsions), and water were obtained by microfluidization. DSPE-PEG was found to play a crucial role on the size and polydispersity index of nanocarriers. Nucleic acids were complexated by adsorption at different charge ratios. No significant differences were noticed in the physicochemical properties of nanocarriers (i.e. droplet size, polydispersity index, or zeta potential) when a single plasmid or both plasmid and oligonucleotide were adsorbed to the formulations. Transmission electron microscopy photomicrographs suggested round nanostructures with the nucleic acids and DSPE-PEG enfolding the surface. Complexes at +4/-1 charge ratio protected nucleic acids against DNase I degradation. The oligonucleotide seemed to be released from the liposomal complexes, while nanoemulsions only released the plasmid after 24 and 48 h of incubation in DMEM supplemented or not. In vitro experiments demonstrated that complexes were highly tolerable to human fibroblasts, Hep-G2, and HEK-293 cells, demonstrating also an uptake ability of about 30%, 30%, and 90%, respectively, no matter what the formulation or the combination of nucleic acids used. Transfection efficiency of the formulations was around 25% in human fibroblasts, 32% in HEK-293, and 15% in Hep-G2 cells. The overall results demonstrated the behavior of liposomes and nanoemulsions complexed with a plasmid or a mixture of a plasmid and an oligonucleotide, and demonstrated that the association with one or two nucleic acids sequences of different length does not seem to interfere in the physicochemical characteristics of complexes or in the uptake capacity by three different types of cells.
European Journal of Pharmaceutical Sciences | 2018
Dirnete Diel; Valeska Lizzi Lagranha; Roselena Silvestri Schuh; Fernanda Bruxel; Ursula da Silveira Matte; Helder Ferreira Teixeira
ABSTRACT Mucopolysaccharidosis type I (MPS I) is an autosomal recessive disease caused by deficiency of &agr;‐l‐iduronidase (IDUA), which results in the lysosomal accumulation of glycosaminoglycans (GAG) leading to widespread clinical manifestations. The microencapsulation of IDUA overexpressing recombinant cells has been considered as a promising strategy for the treatment of MPS I. This study aimed at the optimization of alginate microcapsules containing recombinant BHK (Baby Hamster Kidney) cells (rBHK) overexpressing IDUA produced by electrostatic extrusion technique. The alginate microcapsule (MC‐A) optimization study was carried out by means of an experimental Box‐Behnken Design that allowed the simultaneous evaluation of the influence of voltage (kV), alginate/cell suspension flow (mL/h), and alginate concentration (%) on size and IDUA activity. The optimal conditions of voltage (10 kV), flow (25 mL/h), and alginate concentration (1.3%) made possible to obtain the smallest microcapsules showing the highest IDUA activity. After optimization, the microcapsules were sequentially coated with PLL and alginate (MC‐APA) to increase their stability. MC‐A and MC‐APA presented monodisperse populations (span < 1.22) with an average diameter of less than 350 &mgr;m. The coating increased the mechanical stability of MC‐APA by about 6‐fold and modulated the permeability to the enzyme. Surface analyzes of MC‐APA showed the presence of PLL bands, suggesting that the last alginate layer appears to have only partially coated the PLL. After 30 days of subcutaneous implantation of the MC‐APA microcapsules containing rBHK cells in a MPS I murine model, a significant increase in IDUA activity was observed in the skin near the implant. Histological analysis revealed an inflammatory infiltrate at the application site, which did not prevent the release of the enzyme under the conditions evaluated. Taken together, the overall results demonstrate the feasibility of MC‐APA as a potential alternative for local treatment of MPS I. Graphical abstract Figure. No Caption available.